Key Segments:
By Indication
-
Melanoma
-
Non-small cell lung cancer (NSCLC)
-
Head and neck cancer
-
Hodgkin lymphoma
-
Bladder cancer
-
Others
By Treatment & Administration
-
Monotherapy
-
Combination therapy
-
Intravenous (IV) Injection
-
Subcutaneous Injection
By Strength
-
50 mg per vial
-
100 mg per vial
By End User
-
Hospitals
-
Oncology clinics
-
Research institutions
-
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The Keytruda market was valued at USD 31.51 billion in 2025.
The market is projected to reach USD 87.08 billion by 2035.
The Keytruda market is expected to grow at a CAGR of 10.70% during the forecast period.
Market growth is primarily driven by the rising prevalence of cancer, expanding immunotherapy adoption, increasing approvals for new indications, and ongoing oncology research advancements.
Keytruda is an immunotherapy drug widely used in the treatment of multiple cancers, including lung cancer, melanoma, and head & neck cancers.